Ethics and Compliance
Pfizer's Corporate Ethics and Compliance Program, established under the direction of our Board of Directors, supports our unyielding commitment to high standards of legal and ethical conduct. Strong ethical performance supports our ability to operate in markets around the world and helps protect Pfizer from litigation and negative impacts on our reputation. Our Corporate Compliance Officer and staff provide oversight and guidance to help ensure compliance with applicable laws, regulations and company policies. Colleagues worldwide receive Pfizer's Code of Business Conduct, known as the "Blue Book," which explains Pfizer's commitment to maintaining high standards and performing with integrity. Pfizer has also made considerable investments to prevent bribery and corruption. Our International Anti-Bribery and Anti-Corruption Corporate Procedure implementation platform helps local teams train colleagues and adopt local procedures. We also have established a compliance hotline in 70 countries. These efforts will support our expansion globally and help ensure that Pfizer's business is conducted consistently and ethically around the world.
Pfizer strives to uphold human rights in all of our business activities. We fully support the principles in the Universal Declaration on Human Rights and the International Labour Organization Declaration on Fundamental Principles and Rights at Work. Pfizer is a signatory of the United Nations Global Compact and we support its Ten Principles on human rights, labor, environment and anticorruption.
We believe that people have a right to health, and, while governments may have the primary responsibility, we embrace the unique role Pfizer can play in promoting this right. Our commitment is embodied in the many approaches we have developed to improve access to medicines and strengthen health care systems for underserved people around the world.
Engaging in public policy is a crucial facet of our efforts to create an enabling environment to improve access to medicines and health care. America's current health care system faces real challenges, and we strongly believe that there is long-term value to creating a system that is more efficient, stable and performance oriented. That is why we support health care reform. Reform that expands comprehensive health care coverage, improves quality and provides value for patients, while enhancing choices and health care innovation, is an important goal that benefits patients. Done right, reform can improve Americans' health, broaden access to care and manage costs. Our guiding principle is to support reform that helps many more patients while promoting continued innovation in the search for cures.For more information visit www.pfizer.com/crpolicy
Recognition as a Great Place to Work
Diversity is integral to our business culture, and we consider it a distinct advantage in the marketplace. In addition to numerous individual awards, such as Nikkei's "Woman of the Year" to Pfizer Japan executive Chizuro Kiyomura (pictured), our positive culture and workplace gained recognition by many monitors of the corporate world. Once again, the Working Mother 100 Best Companies roster includes Pfizer, in recognition of our commitment to family-friendly benefits. For the sixth consecutive year, Pfizer earned the highest possible score in the Human Rights Campaign Foundation's Corporate Equality Index, which evaluates U.S.-based businesses on their treatment of lesbian, gay, bisexual and transgender employees, investors and customers. Also for the sixth time, the Women's Business Enterprise National Council named Pfizer one of the top corporations for world-class programs that create level playing fields for women's business enterprises. Diversity/Careers magazine recognized Pfizer as a 2009 Best Diversity Company in Engineering & Information Technology. And Universum, a global employer branding company, named Pfizer one of the top 50 most attractive employers, based on a survey of 120,000 business and engineering students from top academic institutions in 11 leading economies.